These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9391693)

  • 21. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells.
    Abouna GM; Kumar MS; al-Abdullah IH; Loose J; Sullivan DK; Phillips K; Yost S; Seirka D
    Transplant Proc; 1995 Oct; 27(5):2676-8. PubMed ID: 7482872
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
    van den Hoogen MW; Hoitsma AJ; Hilbrands LB
    Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Antithymocyte Globulin Induction Dosing Regimens in Kidney Transplantation Patients: A Network Meta-analysis.
    Lee JH; Kim KY; Song JH; Jhee JH; Kim YJ; Park WY; Kim JK; Lee SW; Hwang SD
    Transplant Proc; 2019 Oct; 51(8):2606-2610. PubMed ID: 31439331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation.
    Hooks MA; Wade CS; Millikan WJ
    Pharmacotherapy; 1991; 11(1):26-37. PubMed ID: 1902291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
    Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin.
    Thibaudin D; Alamartine E; de Filippis JP; Diab N; Laurent B; Berthoux F
    Nephrol Dial Transplant; 1998 Mar; 13(3):711-5. PubMed ID: 9550651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring.
    Djamali A; Turc-Baron C; Portales P; Leverson G; Chong G; Clot J; Mourad G
    Transplantation; 2000 Mar; 69(5):799-805. PubMed ID: 10755529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection.
    Midtvedt K; Fauchald P; Lien B; Hartmann A; Albrechtsen D; Bjerkely BL; Leivestad T; Brekke IB
    Clin Transplant; 2003 Feb; 17(1):69-74. PubMed ID: 12588325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
    Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
    Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
    Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study.
    Oertel M; Sack U; Kohlhaw K; Lehmann I; Emmrich F; Berr F; Hauss J; Schwarz R
    Transpl Int; 2002 Oct; 15(9-10):463-71. PubMed ID: 12389078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
    Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
    Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
    Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful use of Orthoclone OKT 3 for steroid-resistant acute rejection in pediatric renal allograft recipients.
    Palmer J; Slook P
    ANNA J; 1992 Aug; 19(4):375-7. PubMed ID: 1520028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients--long term results.
    Samsel R; Pliszczyński J; Chmura A; Korczak G; Włodarczyk Z; Cieciura T; Lagiewska B; Glyda M; Wyzgal J; Paczek L; Durlik M; Rowiński W
    Ann Transplant; 2008; 13(1):32-9. PubMed ID: 18344941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
    Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT
    Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
    Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
    Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.